Giuseppe Bertuglia

🧑‍⚕️MD, Hematology Resident in Turin 🇮🇹. Currently in London 🇬🇧. Focused on #MultipleMyeloma. Hike lover. Cats addicted. Made in Sicily ☀️

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASCO26 #mmsm Oral sessions myeloma

Sustained MRD negativity in FORTE study

Nice to see 1/3 patients with sustained MRD -ve for 3 years and 1/5 for 5 years

[Giuseppe Bertuglia @Bertolo_94]

Happy to celebrate this important achievement by my friend @R_Enomis in the field of MCL. ❤️
Excellent work! 💪

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #EHA2025 | Francesca Gay @unito presents the long-term follow-up from the phase II FORTE trial of carfilzomib induction, consolidation, and maintenance ± ASCT. KRd with ASCT led to a median PFS 99 mo and 75% 8-year OS rate. The PFS benefit was observed across patient subgroups.
Follow our live feed for more updates: https://t.co/PxibyrTu5Y
#mmsm #myeloma #MedEd #MedNews

[Giuseppe Bertuglia @Bertolo_94]

It’s truly exciting to have contributed to the long-term follow-up analysis of the phase II FORTE trial, and to see the results presented by my mentor. Grateful for the opportunity and proud to be part of my research group.
#EHA2025 #FORTE #MultipleMyeloma

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #EHA2025 | Evangelos Terpos @uoaofficial shares the latest update to the EHA-EMN clinical practice guidelines for diagnosis, treatment, and follow-up. Key updates include new guidelines on defining high-risk disease, examinations upon diagnosis, monitoring for SMM, quadruplet regimens in NDMM, targeted therapies in early relapse and sequencing immunotherapies.
Follow our live feed for more updates: https://t.co/PxibyrSWgq
#mmsm #myeloma #MedEd #MedNews

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #ASH24 | PRESENTATION
@LucaBertamini @erasmusmcblood presents results from a circulating tumor cell sub-study of the phase III PERSEUS trial.
High circulating tumor cells were associated with a worse prognosis in patients with NDMM. The addition of daratumumab to VRd improves outcomes in both patients with high and low circulating tumor cell levels.
Follow our live feed for more updates: https://t.co/7NOfZTHMg8
#myeloma #mmsm #MedicalCongress

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASH24 #mmsm @ASH_hematology

24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702

This is a nice important analysis of the importance of 24-hr urine as a response assessment

@RahulBanerjeeMD

[Giuseppe Bertuglia @Bertolo_94]

Thrilled to have participated at #Under40inHematology! It was a fantastic chance to connect with young Italian colleagues and expand our network. The environment was, as always, incredibly inspiring and full of stimulating discussions.

[Giuseppe Bertuglia @Bertolo_94]

I'm thrilled to share our case report on a rare cutaneous manifestation in a patient with multiple myeloma.
If you're fascinated by medicine, give it a read!
Well done! @Dagostino_MD

British Journal of Haematology | Wiley Online Library https://t.co/A59faM1Xns

[Giuseppe Bertuglia @Bertolo_94]

@amadouchy @WMIWMF 💪💪

[Re-energising Your Career @career_re]

#AcademicTwitter The Creative Process!😂 #phdlife #phdvoice

[Giuseppe Bertuglia @Bertolo_94]

#Scotland 🏴󠁧󠁢󠁳󠁣󠁴󠁿

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Study of impact of daratumumab on collection & engraftment in myeloma patients undergoing stem cell mobilization w/ G-CSF + plerixafor shows daratumumab does not impair HSC collection nor post-ASCT hematopoietic recovery: https://t.co/t3hsFc8RYV. #mmsm

[Giuseppe Bertuglia @Bertolo_94]

@Myeloma_Doc Thank you for sharing!

[Giuseppe Bertuglia @Bertolo_94]

Waiting for Royal Parks Half Marathon on 13th October #London
Check out my @JustGiving page and please donate if you can. Thank you! https://t.co/GIq4MjVis7

[Giuseppe Bertuglia @Bertolo_94]

@ademarchi74 Imbarazzante

[Cosimo Bartoloni @CosimoBartoloni]

Reputo veramente disgustoso e imbarazzante il trattamento che continua a essere dato in diretta Rai nei confronti di una ragazzina di 19 anni alla quale pare non sia concesso dire che gareggiare alle Olimpiadi sia stata la gioia più bella della sua vita, solo perché ha chiuso 4ª.

[Bachisio Ziccheddu @BachisioZic]

Out in @BloodCancerJnl! Years of collaborations between @SylvesterCancer @univmiami @unito @LaStatale @IstTumori and founded by @AIRC_it – Using #WGS and #Flowcytometry to investigate the genomic and immune factors that contribute to resistance to anti-CD38 MoAbs in #RRMM #mmsm

[Giuseppe Bertuglia @Bertolo_94]

#IDAHOBIT
Against all types of discrimination.

[Giuseppe Bertuglia @Bertolo_94]

>> higher rate of #plerixafor use in patients treated with daratumumab
>> NO difference in mobilization failure between Dara exposed and no Dara exposed patients
>> NO difference in #engraftment between Dara exposed and no Dara exposed patients

[Giuseppe Bertuglia @Bertolo_94]

Happy to share with you our results about mobilization by chemo-free regimen (G-CSF only) in patients with #multiplemyeloma treated with #VTd or #DVTd
Final paper ready soon!
#EMN2024